Introduction
Pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis; median overall survival (OS) is <6 months and has not changed in the last two decades. 1 Recent classification of PDAC into subtypes [2] [3] [4] [5] has identified a genomic homologous recombination deficient (HRD) subtype exhibiting a mutational signature of DNA damage repair deficiency. Germline BRCA1/2 mutations associated tumors representing the most prevalent clinical subgroup. The frequency of pathogenic germline BRCA1/2 mutations is 4.6-6.2% in sporadic PDAC cases, 6, 7 and as high as 10-20% in high-risk populations (e.g., Ashkenazim). 8 The BRCA1/2 proteins are involved in the regulation of DNA damage; DNA double-strand breaks repair via homologous recombination (HR). 9 Whereas HRD associated with BRCA1/2 mutations have increased sensitivity to DNA damaging agents (platinum analogs and PARP inhibitors (PARPi)), clinical progression is seen over the course of disease accompanied by evolving tumor resistance in a substantial proportion of cases. [10] [11] [12] Clinical and preclinical data in BRCA-associated cancers suggest overlapping resistance between platinum agents and PARPi. [13] [14] [15] In our study, we aimed to precisely recapitulate the various clinical scenario (sensitive, innate resistant and acquired resistant) to platinum agents and PARPi in the preclinical setting. Research biopsies for translational research were collected at different time points and PDX models were established. A correlation between disease course at tissue acquisition and response to PARP inhibitor (PARPi)/platinum was demonstrated in vivo.
Results
Liver core needle biopsies or ascites fluid were collected at distinct time points during disease course from six PDAC patients who carry BRCA1/2 germline mutations: BRCA2 c.5946delT (n 5 2), BRCA2 c.7659delC (n 5 1), BRCA1 5266insC (n 5 1), BRCA1 c.68-69delAG (n 5 1) and one patient harbored both the BRCA2 c.5946deT and BRCA1 c.5266insC mutations. All patients received platinum based and/or PARPi treatment during the course of their disease. Clinical characteristics are described in Table 1 .
Patient-derived xenograft (PDX) models were generated. These PDX models resemble the morphologic characteristics of primary PDAC as we previously described. 16 Each model represents a distinct clinical scenario of PDAC, enabling testing the correlation with PARPi/Platinum therapy in a preclinical model. Somatic loss of heterozygosity (LOH) at the BRCA1/2 genes' loci (17q21.31 and 13q13.1, respectively) was demonstrated in PDX1, PDX3, PDX5 and PDX6, whereas PDX2 and PDX4 retained heterozygosity (Table 1) . Whole genome sequencing (WGS) analysis of PDXs demonstrated that models with bi-allelic inactivation of BRCA1/2 (PDX1, PDX3, PDX5 and PDX6) had increased somatic mutational load compared to BRCA models that retained the wild type allele (PDX2 and PDX4). Somatic single nucleotide variants (SNV), indels and structural variants (SV) averaged 14,776, 1,394 and 283 in HRD models and 6,070, 556 and 43 in intact models, respectively (Supporting Information Table S1 and Fig. S1 ). Further hallmarks of HRD were also observed exclusively in the bi-allelic BRCA inactivated models, including a smaller proportion of C > T SNVs (<0.3), and a large number of read level deletions >54 bp and SV deletions sized between 100 bp and 10 kbps, as well as a high number of duplications events sized between 10 kbps and 1 mbp in the BRCA1 inactivated model (Fig. 1) .
The clinical to pre-clinical correlation was evaluated in vivo using PDXs from three representative patients (Fig. 2) . PDX1 was established from a patient na€ ıve to platinum/ PARPi. This patient had a durable response to platinum/ PARPi in the clinic (>10 months). WGS of PDX1 revealed an HRD genome subtype. Sensitivity to PARPi and cisplatin treatments was further demonstrated in vivo with significant reduced tumor mass (p < 0.05, p < 0.01; respectively). PDX2 was established from a patient na€ ıve to platinum/PARPi. This patient had a short-term clinical response to platinum/ PARPi. The genetic signature does not have the characteristics of an HRD subtype. In parallel, only a trend toward tumor growth reduction was demonstrated with PARPi or cisplatin treatment in vivo. PDX3 was generated from a patient who demonstrated a durable response to platinum/ PARPi (11 months). Tissue acquisition was obtained during disease progression at clinical resistance to platinum/PARPi. WGS analysis revealed an HRD genome subtype. Neither PARPi nor cisplatin had an effect on tumor growth in PDX3 model in accordance with the clinical scenario ( Fig. 2i-iv) .
Discussion
Our results demonstrate correlation between clinical disease course in BRCA-mutated PDAC patients and response to therapy in PDX models generated from their metastatic lesions. Generation of PDX models at clinically relevant time-points has importance for translational research of novel therapies to overcome resistance and identifying patients most likely to respond to PARPi/platinum containing agents. Tumors with HRD are highly susceptible to PARPi/platinum What's new? Improving the prognosis of pancreatic ductal adenocarcinoma (PDAC) is challenged in part by limited knowledge of relationships between PDAC subtypes and therapeutic responses. Here, using patient-derived xenograft (PDX) models from BRCA1/2 PDAC patients before and after treatment, the authors describe a correlation between clinical subtypes, therapeutic time points, and responses to platinum and PARP inhibition (PARPi) therapy. In particular, a treatment-naive PDX with homologous recombination deficiency (HRD) was sensitive to platinum/PARPi therapy, whereas no benefit was observed in an HRD-genome PDX with acquired resistance. The findings warrant investigation of the effects of alternative combination therapies selected based on PDAC subtype. 
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with durable anti-tumor responses. However, resistance is observed, thus forming the scientific rationale for the development of combination therapies beyond PARPi. Our further research is focused on elucidation of molecular mechanisms underlying innate and acquired resistance to PARPi utilizing these PDX models. There is also need for the identification of additional therapeutic agents which target DNA repair pathways and the introduction of immune therapeutics due to high mutation burden in this subset of PDAC patients (Supporting Information Fig. S1 ).
Materials and Methods
PDAC patient-derived xenograft (PDX) generation in nude mice
All patients have signed an informed consent and tissue samples were obtained following approval of the institutional ethical committee (Helsinki 4744 and 5539/13) and the Israeli Ministry of Health. All animal studies were approved by the Sheba Medical Center Institutional Animal Care and Use Committee (Helsinki 930/14). Core-needle biopsies (CNB) from metastatic PDAC tissues and malignant ascites were collected from germline BRCA1/2 carrier patients undergoing biopsies and paracentesis, respectively, and subcutaneously implanted into lower flanks of 6-to 7-week-old female nude mice. Xenografts were propagated until reached maximum allowed volume (1.5 cm 3 ), then harvested and serially passaged into new recipient mice. Following three xenograft passages, tumors were cryopreserved in 90% serum at liquid nitrogen for further experiments. All PDX tumors were authenticated by STR analysis to paired germline DNA from patients. (ii) RECIST (response evaluation criteria in solid tumors; mm) and paired CT scans performed at three time points (T0-baseline and T1-T2-on treatment); b. Circos plots display intrachromosomal (red) and interchromosomal (blue) somatic structural variants for each PDX. c. In vivo response to PARPi and cisplatin. Average relative tumor volume as a function of time (days) on treatment (olaparib 50 mg/kg; 5 days a week; I.P.; or cisplatin -2 mg/kg once a week; I.P.; green) and control (gray) (n 5 6-8/group). *p < 0.05; **p < 0.01. [Color figure can be viewed at wileyonlinelibrary.com]
DNA extraction
Peripheral blood leukocyte DNA from the patients and paired PDX DNA were extracted using the DNeasy Blood & Tissue Kit (Qiagen), following the manufacturer's recommended protocol.
Mutation genotyping
At initial diagnosis germline DNA from each patient was subjected to both BRCA1 and BRCA2 sequence analysis by BRACAnalysis CDx TM test for clinical evaluation which was performed by Myriad Genetic Laboratories (Salt Lake City, UT); or mutational analyses which were carried out by restriction enzyme digest of PCR products, to introduce a restriction site that distinguishes between the wild type and the mutant allele and analysis of the digested PCR products on agarose gels as previously described. 17 The mutation resulted in a different fragment pattern from the wild type allele. PDX-derived DNA was analyzed by the aforementioned method. For each of these mutations, a known mutation carrier was used as a positive control in each experiment and each mutation was confirmed by sequencing.
Whole genome sequencing
Whole genome sequencing was performed as described in Denroche et al.
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Histology
CNBs and PDXs were paraffin embedded and serially sectioned at 4 lm for histological and immunocytochemical analyses. Sections were stained with hematoxylin and eosin (H&E) for morphological evaluation.
Therapeutic evaluation in vivo
For each in vivo therapeutic experiment preserved tumor chunks from each PDX model were thawed and implanted to lower flank of 6-week-old female nude mice. When tumors reached palpable size (100 mm 3 ), mice were randomized into treatment groups (n 5 6-8): (a) PARPi (Olaparib, Selleckhem) dissolved in 10% Hydroxypropyl-b-Cyclodextrin (Sigma-Aldrich, Rehovot, Israel), 50 mg/kg, administered via intra-peritoneal (I.P.) injection 5 days a week for 4 weeks. (b) Cisplatin (2 mg/kg, I.P., once a week). (c) Vehicle control (Solvent only, I.P.).
Tumor volumes were measured twice a week using a caliper according to the formula (length 3 width 2 )/2. Mice were weighted twice a week. Mice were euthanized if the tumor burden reached 1.5 cm 3 or the animals presented over 20% of the initial body weight loss. At the end of the experiments, animals were sacrificed by CO 2 inhalation. Tumor growth curves are presented as mean relative tumor volume (RTV)6 SE at each measurement point, for each treatment group.
Mice were purchased from Envigo (Jerusalem, israel) and maintained in specific pathogen-free (SPF) rooms in a temperature-controlled room at 208C with a 12 hr-12 hr dark-light cycle. Animals had free access to water and commercial chow.
Statistical analysis
Differences between treatment groups were analyzed by Mann-Whitney test using GraphPad Prism (Graph Pad Software). Error bars represent SE.
